{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T13:19:49Z","timestamp":1769433589215,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,2,1]],"date-time":"2008-02-01T00:00:00Z","timestamp":1201824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2008,2]]},"DOI":"10.1016\/j.pnpbp.2007.09.007","type":"journal-article","created":{"date-parts":[[2007,9,17]],"date-time":"2007-09-17T12:21:44Z","timestamp":1190031704000},"page":"405-413","source":"Crossref","is-referenced-by-count":50,"title":["Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation"],"prefix":"10.1016","volume":"32","author":[{"given":"Vincenzo","family":"Villari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Rocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Fonzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiana","family":"Montemagni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Pandullo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Bogetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2007.09.007_bib1","unstructured":"Agenzia Italiana del Farmaco \u2014 AIFA (2007). Linee guida per gli studi osservazionali sui farmaci.http:\/\/www.agenziafarmaco.it\/aifa)."},{"key":"10.1016\/j.pnpbp.2007.09.007_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0924-977X(01)00097-9","article-title":"Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials","volume":"11","author":"Aleman","year":"2001","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 14","key":"10.1016\/j.pnpbp.2007.09.007_bib3","first-page":"11","article-title":"Managing the agitated psychotic patient: a reappraisal of the evidence (Review)","volume":"61","author":"Allen","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib4","first-page":"quiz 89","article-title":"Consensus Panel for Behavioral Emergencies. The Expert Consensus Guideline Series. Treatment of behavioral emergencies","volume":"1\u201388","author":"Allen","year":"2001","journal-title":"Postgrad Med"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00131746-200301000-00005","article-title":"What do consumers say that they want and need during a psychiatric emergency?","volume":"9","author":"Allen","year":"2003","journal-title":"J Psychiatr Pract"},{"issue":"suppl 1","key":"10.1016\/j.pnpbp.2007.09.007_bib6","first-page":"1","article-title":"The Expert Consensus Guideline Series: treatment of behavioral emergencies","volume":"11","author":"Allen","year":"2005","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib7","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jama.290.7.921","article-title":"Association of funding and conclusions in randomized drug trials","volume":"290","author":"Als-Nielsen","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/00003495-200363050-00004","article-title":"Intramuscular preparations of antipsychotics: uses of relevance in clinical practice","volume":"63","author":"Altamura","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib9","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0006-3223(97)00190-X","article-title":"Multiple fixed doses of \u2018Seroquel\u2019 (quetiapine) in patients with acute exarcebation of schizophrenia: a comparison with haloperidol and placebo","volume":"42","author":"Arvanitis","year":"1997","journal-title":"Biol Psychiatry"},{"issue":"Suppl. 4","key":"10.1016\/j.pnpbp.2007.09.007_bib10","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.1097\/01.jcp.0000085406.08426.a8","article-title":"Effectiveness of rapid initial dose escalation of up to 40\u00a0mg per day of oral olanzapine in acute agitation","volume":"23","author":"Baker","year":"2003","journal-title":"J Clin Psychopharmacol"},{"issue":"suppl. 3","key":"10.1016\/j.pnpbp.2007.09.007_bib11","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/00004850-199803003-00009","article-title":"Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia","volume":"13","author":"Barnes","year":"1998","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1592\/phco.21.7.717.34575","article-title":"Ziprasidone, a new atypical antipsychotic drug","volume":"21","author":"Carnahan","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pnpbp.2007.09.007_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00004850-200211000-00004","article-title":"Treatment of severely psychotic inpatients with schizophrenia. Olanzapine versus other antipsychotic drugs","volume":"17","author":"Carrasco","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib15","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0149-2918(03)80094-2","article-title":"A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia","volume":"25","author":"Chengappa","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1176\/appi.ps.51.6.717","article-title":"Physical and chemical restraint in the Psychiatric Emergency Service","volume":"51","author":"Currier","year":"2000","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00131746-200601000-00005","article-title":"Orally versus intramuscularly administered antipsychotic drugs in psychiatric emergencies","volume":"12","author":"Currier","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4088\/JCP.v62n0303","article-title":"Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation","volume":"62","author":"Currier","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib18","doi-asserted-by":"crossref","first-page":"386","DOI":"10.4088\/JCP.v65n0315","article-title":"Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam","volume":"65","author":"Currier","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib20","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3758\/BF03203630","article-title":"G\u204ePOWER: a general power analysis program","volume":"28","author":"Erdfelder","year":"1996","journal-title":"Behav Res Meth Instrum Comput"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/13651500510029011","article-title":"Effectiveness of quetiapine for the management of aggressive psychosis in the emergency psychiatric setting: a naturalistic uncontrolled trial","volume":"9","author":"Ganesan","year":"2005","journal-title":"Int J Psychiatry Clin Pract"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib23","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.pnpbp.2007.09.007_bib24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/0269881105048897","article-title":"Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study","volume":"19","author":"Hovens","year":"2005","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pnpbp.2007.09.007_bib25","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1055\/s-2007-979317","article-title":"Severe akathisia during olanzapine treatment of acute schizophrenia","volume":"31","author":"Jauss","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib26","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"suppl 2","key":"10.1016\/j.pnpbp.2007.09.007_bib27","first-page":"12","article-title":"Rapid tranquilization with olanzapine in acute psychosis: a case series","volume":"62","author":"Karagianis","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.pnpbp.2007.09.007_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1080\/15622970500355417","article-title":"Treatment challenges in the acute hospital setting","volume":"6","author":"Kasper","year":"2005","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib29","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00005053-198809000-00007","article-title":"Profiles of aggression among psychiatric patients. I. Nature and prevalence","volume":"176","author":"Kay","year":"1988","journal-title":"J Nerv Ment Dis"},{"issue":"4","key":"10.1016\/j.pnpbp.2007.09.007_bib30","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1176\/appi.ajp.160.4.741","article-title":"Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial","volume":"160","author":"Keck","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib31","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ajem.2004.02.021","article-title":"Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia","volume":"22","author":"Kinon","year":"2004","journal-title":"Am J Emerg Med"},{"issue":"5","key":"10.1016\/j.pnpbp.2007.09.007_bib32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.yic.0000138820.78121.0e","article-title":"Oral risperidone plus oral lorazepam versus standard care with intramuscular conventional neuroleptics in the initial phase of treating individuals with acute psychosis","volume":"19","author":"Lejeune","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1192\/bjp.bp.105.019307","article-title":"Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia","volume":"189","author":"McCue","year":"2006","journal-title":"Br J Psychiatry"},{"issue":"suppl. 1","key":"10.1016\/j.pnpbp.2007.09.007_bib36","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatment for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib37","unstructured":"National Institute of Mental Health (1976). CGI: clinical global impressions. In Guy W (ed.), ECDEU Assessment Manual of Psychopharmacology, rev. edn. US Department of Health, Education and Welfare Publication (ADM) 76\u201338. National Institute of Mental Health, Rockville, MD. 217\u2013222."},{"key":"10.1016\/j.pnpbp.2007.09.007_bib38","first-page":"97","article-title":"The Brief Psychiatric Rating Scale. Recent developments in ascertaining and scaling","volume":"24","author":"Overhall","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib39","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hup.509","article-title":"Comparison of three antipsychotic in the emergency psychiatric setting","volume":"18","author":"Raja","year":"2003","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib40","doi-asserted-by":"crossref","first-page":"191","DOI":"10.2165\/00023210-199809030-00003","article-title":"Current concepts in the pharmacotherapy of acute psychosis","volume":"9","author":"Remington","year":"1998","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pnpbp.2007.09.007_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side-effects","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.pnpbp.2007.09.007_bib41","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.pnpbp.2006.01.015","article-title":"Managing the aggressive and violent patient in the psychiatric emergency","volume":"30","author":"Rocca","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib46","series-title":"SPSS Inc.","article-title":"SPSS Base 11.5 for Windows User's Guide","author":"SPSS Inc","year":"2002"},{"issue":"12","key":"10.1016\/j.pnpbp.2007.09.007_bib47","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1345\/aph.1E258","article-title":"Intramuscular olanzapine in the management of acute agitation","volume":"38","author":"Tulloch","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.pnpbp.2007.09.007_bib43","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1176\/appi.ajp.158.7.1149","article-title":"Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia","volume":"158","author":"Wright","year":"2001","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2007.09.007_bib44","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/emj.20.4.339","article-title":"Pharmacological management of agitation in emergency settings","volume":"20","author":"Yildiz","year":"2003","journal-title":"Emerg Med J"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607003375?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584607003375?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,4]],"date-time":"2019-01-04T03:30:45Z","timestamp":1546572645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584607003375"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["S0278584607003375"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2007.09.007","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2]]}}}